Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, reported during the second quarter of 2023 --
-- Phase 3 SYNCHRONY studies on track to begin enrolling in the second half of 2023 --
-- 36 Weeks Results from the Phase 2b SYMMETRY study, evaluating treatment of patients with compensated cirrhosis due to NASH, on track to be reported in the fourth quarter of this year --
-- $334.8 million in net proceeds raised through Akero’s ATM Facility and underwritten registered direct offering of common stock --
https://finance.yahoo.com/news/akero-therapeutics-reports-second-quarter-100000378.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.